<DOC>
	<DOC>NCT00263211</DOC>
	<brief_summary>The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.</brief_summary>
	<brief_title>A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Women with metastatic breast cancer who are completing planned course of chemotherapy with planned treatment break On stable hormone therapy for at least 2 months are also eligible for the study Estimated survival of at least 3 months No platelet inhibitor therapy within 1 month of study entry Platelets ≥ 100,000 Coagulation screening tests within normal range (INR between 0.81 and 1.20) Normal kidney and liver function as defined by: Aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT))/alanine aminotransferase(ALT) ≤ 2 x Institutional Normal Creatinine ≤ 2 x Institutional Normal Able to provide signed, informed consent. Patients going on to surgery Patients with a serious bleeding disorder that make them inappropriate candidates for NSAID therapy Patients with history of significant bleeding related to peptic ulcer disease Patients on standing doses of NSAIDS or platelet function inhibitors Patients on standing doses of anticoagulants</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Platelet</keyword>
</DOC>